Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 17

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 17
---
 Aptorum Group. •“AD” refers to Alzheimer’s disease. •“Aeneas Group” refers to Aeneas Limited and its subsidiaries. Aeneas Limited is 76.8% owned by Jurchen Investment Corporation. Because Mr. Huen, a director, holds 100% equity interest in Jurchen Investment Corporation, we refer Aeneas Group as a subsidiary of Aptorum Group. •“AML” refers to Aptorum Medical Limited, a 90% owned subsidiary of Aptorum Group, as of the date of this proxy statement/prospectus. •“Aptorum Class A ordinary shares” refers to Aptorum’s Class A ordinary shares, par value $0.00001 per share. •“Aptorum Class B ordinary shares” refers to Aptorum’s Class B ordinary shares, par value $0.00001 per share. •“Aptorum Delaware common stock” refers to common stock of Aptorum Delaware, par value $0.000 per share. •“Aptorum ordinary shares” refers to Aptorum Class A ordinary shares and Aptorum Class B ordinary shares •“CAP” refers to College of Clinical Pathology (CAP) accredited laboratory •“cGCP” refers to Current Good Clinical Practice as adopted by the applicable regulatory authority. •“cGLP” refers to Current Good Laboratory Practice as adopted by the applicable regulatory authority. •“cGMP” refers to Current Good Manufacturing Practice as adopted by the applicable regulatory authority. •“Combined Company” refers to the Company immediately following the consummation of the Merger. •“CLIA” refers to Clinical Laboratory Improvement Amendments. •“Company,” “we” and “us” and “our” refer to Aptorum Group Limited, currently a Cayman Islands exempted company with limited liability whose principal place of business is in Hong Kong, but which will be a company incorporated in Delaware after the Domestication. •“CMC” refers to chemical, manufacturing and control. •“Covar” refers to Covar Pharmaceuticals Incorporated, a contract research organization engaged by the Company. •“CROs” refers to contract research organizations. •“CTA” refers to Clinical Trial Application. •“DiamiR” refers to DiamiR Biosciences Corp., a Delaware corporation and its wholly -ownedsubsidiary DiamiR, LLC a private Delaware limited liability company. •“Merger” means the merger contemplated by that certain merger agreement (“Merger Agreement”) by and